Only 20 full-company mergers or acquisitions occurred throughout the year, although asset acquisition deals were more common.

Last week, readers were most interested in Labcorp's acquisition of assets from MAWD, a CE mark for Roche's mass spec system, and features on Volition and Siemens Healthineers.

The agency made multiple decisions regarding coverage for diagnostic and laboratory testing that have affected the industry.

Consolidation within the industry also remained brisk as cost and reimbursement concerns provided acquisition opportunities for large national outfits.

The firm also has plans for tests beyond sepsis, including for cardiac events and other conditions that are commonly treated in acute care settings.

The companies said they plan to explore a range of questions including the clinical implementation of the Alzheimer's disease biomarker phosphorylated tau 217.

The company consolidated its instrument lineup with its newer Atellica instruments and is phasing out support for Advia and Dimension branded analyzers through 2030.

Labcorp will acquire portions of the lab's clinical and women's health testing businesses, while MAWD will continue to provide anatomic and other pathology services.

Top Five Articles on 360Dx Last Week: Labcorp Asset Acquisition, Roche CE Mark for Mass Spec, More Last week, readers were most interested in Labcorp's acquisition of assets from MAWD, a CE mark for ...

The firm also has plans for tests beyond sepsis, including for cardiac events and other conditions that are commonly treated in acute care settings. Becton Dickinson's HPV assay was FDA-approved for ...

NEW YORK – As implementation of the US Food and Drug Administration's final rule on laboratory-developed tests (LDTs) continues amidst legal challenges from several industry stakeholders, efforts are ...

For full-year 2024, total investment in these spaces rose by 27 percent with both the number of deals and the average deal size growing year over year. Called the Coalition for Effective Diagnostics, ...